Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple myeloma | — | D009101 | C90.0 |
non-hodgkin lymphoma | — | D008228 | C85.9 |
Code | Description |
---|---|
J2562 | Injection, plerixafor, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 5 | 25 | 4 | — | 11 | 43 |
Myeloid leukemia acute | D015470 | — | C92.0 | 16 | 14 | 1 | — | 2 | 25 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | 9 | 7 | 1 | — | — | 13 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 4 | 6 | 1 | — | 2 | 12 |
Neutropenia | D009503 | — | D70 | 2 | 2 | 1 | — | — | 3 |
Infections | D007239 | EFO_0000544 | — | 1 | 2 | 1 | — | — | 2 |
Warts | D014860 | — | B07 | 1 | 2 | 1 | — | — | 2 |
Agammaglobulinemia | D000361 | HP_0004313 | D80.1 | — | 1 | 1 | — | — | 1 |
Transplantation | D014180 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hodgkin disease | D006689 | — | C81 | 3 | 11 | — | — | 2 | 14 |
Myelodysplastic syndromes | D009190 | — | D46 | 6 | 7 | — | — | 2 | 13 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | 4 | — | — | 2 | 10 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 3 | 4 | — | — | 1 | 7 |
Fanconi anemia | D005199 | Orphanet_84 | D61.09 | 4 | 4 | — | — | — | 5 |
Healthy volunteers/patients | — | — | — | 3 | 2 | — | — | — | 5 |
Glioblastoma | D005909 | EFO_0000515 | — | 3 | 3 | — | — | — | 4 |
Gliosarcoma | D018316 | — | — | 3 | 3 | — | — | — | 4 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | 1 | 4 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 1 | — | — | 2 | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | — | — | — | 2 | 3 |
Hairy cell leukemia | D007943 | — | C91.4 | 1 | — | — | — | 2 | 3 |
Burkitt lymphoma | D002051 | — | C83.7 | 1 | — | — | — | 2 | 3 |
Large-cell lymphoma immunoblastic | D016400 | — | — | 1 | — | — | — | 2 | 3 |
Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 1 | — | — | — | 1 | 2 |
Lymphomatoid granulomatosis | D008230 | — | C83.8 | 1 | — | — | — | 1 | 2 |
Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
Oligodendroglioma | D009837 | EFO_0000631 | — | 1 | — | — | — | — | 1 |
Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | — | — | — | — | 1 |
Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | — | — | — | — | 1 | 1 |
Large-cell lymphoma anaplastic | D017728 | — | C84.6 | — | — | — | — | 1 | 1 |
T-cell lymphoma peripheral | D016411 | — | — | — | — | — | — | 1 | 1 |
Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | — | — | — | — | 1 | 1 |
Large granular lymphocytic leukemia | D054066 | — | — | — | — | — | — | 1 | 1 |
Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | — | — | — | 1 | 1 |
Paraproteinemias | D010265 | — | D47.2 | — | — | — | — | 1 | 1 |
Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | — | — | — | — | 1 | 1 |
Myeloid leukemia chronic-phase | D015466 | — | — | — | — | — | — | 1 | 1 |
Myeloid leukemia accelerated phase | D015465 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Plerixafor |
INN | plerixafor |
Description | Plerixafor is an azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. It has a role as an immunological adjuvant, an antineoplastic agent, an anti-HIV agent and a C-X-C chemokine receptor type 4 antagonist. It is an azamacrocycle, a crown amine, a secondary amino compound, an azacycloalkane, a tertiary amino compound and a member of benzenes. It is functionally related to a 1,4,8,11-tetraazacyclotetradecane. |
Classification | Small molecule |
Drug class | CXCR receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1 |
PDB | — |
CAS-ID | 110078-46-1 |
RxCUI | — |
ChEMBL ID | CHEMBL18442 |
ChEBI ID | — |
PubChem CID | 65015 |
DrugBank | DB06809 |
UNII ID | S915P5499N (ChemIDplus, GSRS) |